Smart PSA boosted targeted screening and found more aggressive prostate cancers in Black men in Chicago trials.
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a ...
The prostate is the single organ most frequently afflicted by cancer in men. Prostate cancer affects approximately 4 million ...
How much a stock's price changes over time is important for most investors, since price performance can both impact your ...
Sponsor activations are common in auto racing and all modern sports. This one, however, could literally save lives.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual ...
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, ...
May 27 (Reuters) - Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the ...
Researchers Moffitt Cancer Center have reported encouraging early results from a clinical trial testing whether immunotherapy can improve treatment for men with one of the most dangerous forms of ...
Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy can improve results when added to a radiotherapy-based treatment regimen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results